Journal of Cachexia, Sarcopenia and Muscle (JCSM) Abstract
Article first published online: 08 July 2019
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
Xiaoling Zhong, Marianne Pons, Christophe Poirier, Yanlin Jiang, Jianguo Liu, George E. Sandusky, Safi Shahda, Attila Nakeeb, C. Max Schmidt, Michael G. House, Eugene P. Ceppa. Nicholas J. Zyromski, Yunlong Liu, Guanglong Jiang, Marion E. Couch, Leonidas G. Koniaris, Teresa A. Zimmers
Pancreatic ductal adenocarcinoma (PDAC) is a particularly lethal malignancy partly due to frequent, severe cachexia. Serum activin correlates with cachexia and mortality, while exogenous activin causes cachexia in mice.
Isoform‐specific activin expression and activities were queried in human and murine tumours and PDAC models. Activin inhibition was by administration of soluble activin type IIB receptor (ACVR2B/Fc) and by use of skeletal muscle specific dominant negative ACVR2B expressing transgenic mice. Feed‐forward activin expression and muscle wasting activity were tested in vivo and in vitro on myotubes.
Murine PDAC tumour‐derived cell lines expressed activin‐βA but not activin‐βB. Cachexia severity increased with activin expression. Orthotopic PDAC tumours expressed activins, induced activin expression by distant organs, and produced elevated serum activins. Soluble factors from PDAC elicited activin because conditioned medium from PDAC cells induced activin expression, activation of p38 MAP kinase, and atrophy of myotubes. The activin trap ACVR2B/Fc reduced tumour growth, prevented weight loss and muscle wasting, and prolonged survival in mice with orthotopic tumours made from activin‐low cell lines. ACVR2B/Fc also reduced cachexia in mice with activin‐high tumours. Activin inhibition did not affect activin expression in organs. Hypermuscular mice expressing dominant negative ACVR2B in muscle were protected for weight loss but not mortality when implanted with orthotopic tumours. Human tumours displayed staining for activin, and expression of the gene encoding activin‐βA (INHBA) correlated with mortality in patients with PDAC, while INHBB and other related factors did not.
Pancreatic adenocarcinoma tumours are a source of activin and elicit a systemic activin response in hosts. Human tumours express activins and related factors, while mortality correlates with tumour activin A expression. PDAC tumours also choreograph a systemic activin response that induces organ‐specific and gene‐specific expression of activin isoforms and muscle wasting. Systemic blockade of activin signalling could preserve muscle and prolong survival, while skeletal muscle‐specific activin blockade was only protective for weight loss. Our findings suggest the potential and need for gene‐specific and organ‐specific interventions. Finally, development of more effective cancer cachexia therapy might require identifying agents that effectively and/or selectively inhibit autocrine vs. paracrine activin signalling.
Zhong, X., Pons, M., Poirier, C., Jiang, Y., Liu, J., Sandusky, G. E., Shahda, S., Nakeeb, A., Schmidt, C. M., House, M. G., Ceppa, E. P., Zyromski, N. J., Liu, Y., Jiang, G., Couch, M., Koniaris, L. G., and Zimmers, T. A. ( 2019) The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy, Journal of Cachexia, Sarcopenia and Muscle, 10: 1083– 1101. https://doi.org/10.1002/jcsm.12461.